Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
398 stopped studies mapped to Sarcoma and descendants · 90% state a reason
Over the 398 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05691478 | A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With… | Phase 2 / Phase 3 | suspended | Jan 20, 2023 | National Cancer Institute (NCI) | Other - Extend the observation period for current patients | Other (stated, no rule matched) |
| NCT05264974 | Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization | Phase 1 | suspended | Mar 3, 2022 | University of Florida | seeking additional funding | Funding |
| NCT07297160 | CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors(CALySSEY) | Phase 1 | withdrawn | Dec 22, 2025 | Baylor College of Medicine | The study was revised into two separate protocols to separate treatments. We will submit as… | Other (stated, no rule matched) |
| NCT06968988 | Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic… | Phase 1 | suspended | May 13, 2025 | Washington University School of Medicine | Protocol amendment | Other (stated, no rule matched) |
| NCT05813327 | Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma | Phase 1 | terminated | Apr 14, 2023 | Washington University School of Medicine | Polaris decided to close to accrual. | Enrollment / accrual |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR…(POTENTIATE) | Phase 1 | terminated | Apr 25, 2023 | Boundless Bio, Inc. | Decision was made to halt the study based on overall clinical experience and market considerations.… | Safety / toxicity |
| NCT04539366 | Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children,… | Phase 1 | suspended | Sep 7, 2020 | National Cancer Institute (NCI) | Other - review of safety data | Safety / toxicity |
| NCT05703854 | Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction… | Phase 1 / Phase 2 | suspended | Jan 30, 2023 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT05026736 | Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma,… | Phase 2 | terminated | Aug 30, 2021 | M.D. Anderson Cancer Center | PI request, \<75% participation | Other (stated, no rule matched) |
| NCT05109494 | Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas | Phase 2 | suspended | Nov 5, 2021 | University of Wisconsin, Madison | Administrative | Other (stated, no rule matched) |
| NCT04037527 | Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the… | Phase 1 | terminated | Jul 30, 2019 | Wake Forest University Health Sciences | Terminated due DLTs | Other (stated, no rule matched) |
| NCT04751383 | Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in… | Phase 1 | terminated | Feb 12, 2021 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT05712694 | Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With… | Phase 3 | terminated | Feb 3, 2023 | Polaris Group | Lack of Efficacy, no safety concern. | Safety / toxicity |
| NCT01012297 | Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients… | Phase 3 | terminated | Nov 13, 2009 | National Cancer Institute (NCI) | The study was targeted to accrue 130 patients, but closed early for futility. | Efficacy / futility |
| NCT05130255 | GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 | Phase 1 | terminated | Nov 23, 2021 | Y-mAbs Therapeutics | Decision by Sponsor | Other (stated, no rule matched) |
| NCT07136571 | Phase I Study of Safety and Feasibility of Transarterial Embolization of Incurable… | N/A | withdrawn | Aug 22, 2025 | University of Alabama at Birmingham | Study PI is leaving UAB and no longer opening study. | Other (stated, no rule matched) |
| NCT05549921 | Phase II Study of TAEST16001 in Soft Tissue Sarcoma | Phase 2 | terminated | Sep 22, 2022 | Sun Yat-sen University | The study was terminated due to initiation of a new clinical trial with an updated study design. | Other (stated, no rule matched) |
| NCT05941325 | A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With… | Phase 2 | suspended | Jul 12, 2023 | Shanghai 6th People's Hospital | Recruitment is temporarily suspended to allow for operational adjustments at the study sites. The… | Enrollment / accrual |
| NCT01412515 | A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral… | Phase 2 | terminated | Aug 9, 2011 | Institut National de la Santé Et de la Recherche Médicale, France | results from interim analysis conducted to study interruption | Efficacy / futility |
| NCT04123535 | Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma(HIFU-UPS) | N/A | terminated | Oct 11, 2019 | Matthew Bucknor | Slow accrual | Enrollment / accrual |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in… | Phase 1 | terminated | Mar 13, 2012 | M.D. Anderson Cancer Center | \< 75 % participation | Other (stated, no rule matched) |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced… | Phase 2 | terminated | Oct 8, 2024 | OHSU Knight Cancer Institute | Loss of support. | Other (stated, no rule matched) |
| NCT05879185 | A Study of XmAb23104 in People With Sarcoma | Phase 2 | terminated | May 30, 2023 | Memorial Sloan Kettering Cancer Center | Vendor decided study to be closed early | Other (stated, no rule matched) |
| NCT06341712 | Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma(CabOSTar) | Phase 2 | terminated | Apr 2, 2024 | Ipsen | The sponsor has decided to terminate the CabOSTar study due to ongoing recruitment challenges | Enrollment / accrual |
| NCT01612481 | Phase II Study Evaluating Strategies of Lung Surveillance of Patients Operated of High…(CASSANDRE) | Phase 2 | terminated | Jun 5, 2012 | Centre Oscar Lambret | lack of enrollment | Enrollment / accrual |
| NCT04890093 | Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults… | Phase 1 / Phase 2 | suspended | May 18, 2021 | National Cancer Institute (NCI) | Pending updated agreements in order to enroll additional participants. | Enrollment / accrual |
| NCT03652298 | Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative…(NeuroPrevPTSD) | Phase 2 | terminated | Aug 29, 2018 | Centre Oscar Lambret | Lack of recruitment and of study staff | Enrollment / accrual |
| NCT05799612 | Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous… | Phase 1 | withdrawn | Apr 5, 2023 | M.D. Anderson Cancer Center | No participants enrolled | Enrollment / accrual |
| NCT05116254 | Sarcomas and DDR-Inhibition; a Combined Modality Study(SADDRIN-1) | Phase 1 | terminated | Nov 10, 2021 | The Netherlands Cancer Institute | Endpoint has been reached. | Other (stated, no rule matched) |
| NCT05846724 | Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma(PULSAR) | Phase 2 | withdrawn | May 6, 2023 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | The lack of adequate funding has made it impossible to continue with the clinical study As this… | Funding |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory… | Phase 1 | terminated | Apr 6, 2015 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally… | Phase 1 / Phase 2 | terminated | Feb 7, 2020 | Ocellaris Pharma, Inc. | Business Decision | Sponsor / business decision |
| NCT05481645 | Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib… | Phase 2 | terminated | Aug 1, 2022 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns. | Safety / toxicity |
| NCT04204941 | Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced… | Phase 1 | terminated | Dec 19, 2019 | Epizyme, Inc. | FDA and Ipsen alignelment: Due to unfeasibility and the resulting inability to meet the required… | Safety / toxicity |
| NCT06438783 | TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic… | Phase 1 | terminated | Jun 3, 2024 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT06050434 | Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With…(PROTraSarc) | — | terminated | Sep 22, 2023 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | The study was terminated prematurely due to slow recruitment after inclusion of 7 patients (of… | Enrollment / accrual |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in… | Phase 1 / Phase 2 | terminated | Jan 26, 2021 | Transgene | Sponsor decision following completion of Phase I part not driven by safety reason | Safety / toxicity |
| NCT05496569 | TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma | Phase 2 | terminated | Aug 11, 2022 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | HiFiBiO Therapeutics | The decision to discontinue the trial was made as part of a strategic review of the Sponsor's… | Safety / toxicity |
| NCT03514407 | A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma | Phase 1 | terminated | May 2, 2018 | Incyte Corporation | Strategic Business Decision | Sponsor / business decision |
| NCT06275854 | YASU Research Registry: For Young Adults With Cancer | — | terminated | Feb 23, 2024 | Young Adult Survivors United | Sponsoring organization no longer desired to recruit/maintain registry | Enrollment / accrual |
| NCT06511388 | Cardiotoxic Effects of Chemotherapy in Patients With Sarcomas: A Two and… | — | terminated | Jul 22, 2024 | Mayo Clinic | Low accrual | Enrollment / accrual |
| NCT06058728 | A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules…(Pink Orchid) | — | withdrawn | Sep 28, 2023 | AbbVie | Company Decision | Sponsor / business decision |
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | Phase 2 | withdrawn | Oct 16, 2023 | Institut Bergonié | Discontinuation of molecule development | Other (stated, no rule matched) |
| NCT06670976 | Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients… | Phase 1 | withdrawn | Nov 1, 2024 | Roswell Park Cancer Institute | to be submitted at a later date | Other (stated, no rule matched) |
| NCT05605522 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | Phase 1 | terminated | Nov 4, 2022 | 3B Pharmaceuticals GmbH | Sponsor reprioritization of active trials. | Other (stated, no rule matched) |
| NCT02784795 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | terminated | May 27, 2016 | Eli Lilly and Company | The study was terminated due to business considerations | Sponsor / business decision |
| NCT05017246 | Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural… | Phase 2 | terminated | Aug 23, 2021 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT03862131 | PROactive Evaluation of Function to Avoid CardioToxicity(PROACT) | Phase 2 | terminated | Mar 5, 2019 | Washington University School of Medicine | Insufficient funding/staff | Funding |
| NCT03194646 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 6) | Phase 3 | terminated | Jun 21, 2017 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 1 hour agoSource updated Sep 29, 2026source: clinicaltrials